Cryo-Cell International (STU:ZCY) ROCE %: 4.96% (As of Feb. 2026)

What is Cryo-Cell International ROCE %?

Cryo-Cell International STU:ZCY -23.87% 58 ROCE % is 4.96% as of Feb. 2026. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.06 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cryo-Cell International's annualized ROCE % for the quarter that ended in Feb. 2026 was 4.96%.

Cryo-Cell International (STU:ZCY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cryo-Cell International ROCE % Related Terms

Cryo-Cell International ROCE % Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International ROCE % Chart

Cryo-Cell International Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Nov25

ROCE %

Get a 7-Day Free Trial

11.67

11.99

-27.39

11.30

-0.61

Cryo-Cell International Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
ROCE %	Get a 7-Day Free Trial															9.69	10.14	15.53	-38.45	4.96

58GF Score

Cryo-Cell International Inc STU:ZCY

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cryo-Cell International ROCE % Calculation

Cryo-Cell International's annualized ROCE % for the fiscal year that ended in Nov. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Nov. 2025 )		(A: Nov. 2024 )		(A: Nov. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Nov. 2025 )		(A: Nov. 2024 )		(A: Nov. 2025 )
	=	-0.234	/	( ( (60.927 - 20.347)	+	(53.396 - 17.121) )	/ 2 )
	=	-0.234	/	( (40.58	+	36.275)	/ 2 )
	=	-0.234	/	38.4275
	=	-0.61 %

Cryo-Cell International's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	1.804	/	( ( (53.396 - 17.121)	+	(51.509 - 15.028) )	/ 2 )
	=	1.804	/	( ( 36.275	+	36.481 )	/ 2 )
	=	1.804	/	36.378
	=	4.96 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 4.96% mean?

Cryo-Cell International (STU:ZCY) has a ROCE % of 4.96% as of Feb. 2026.

Is Cryo-Cell International's ROCE % too high?

Cryo-Cell International's current ROCE % is 4.96%. The Healthcare Providers & Services industry median ROCE % is 6.43. Cryo-Cell International's value of 4.96% is 22.9% below this industry median. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cryo-Cell International's ROCE % compare to CCM and CDIX?

Cryo-Cell International's ROCE % of 4.96% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.43. Cryo-Cell International's value of 4.96% is 22.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.43, based on 645 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current ROCE % of 4.96% is 22.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current ROCE % is 4.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cryo-Cell International stock overvalued right now?

Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.06, compared to a current price of €2.36 — trading 41.9% below its estimated fair value. The current ROCE % is 4.96% and 22.9% below the Healthcare Providers & Services industry median of 6.43. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current ROCE % is 4.96% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.36 is trading 41.9% below its estimated GF Value™ of €4.06. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

ROCE %: 4.96%
GF Value™: €4.06 vs. price of €2.36 (41.9% below fair value)
GF Score™: 58/100 with 5 warning signs
Industry Position: 22.9% below the Healthcare Providers & Services median

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies CCM CDIX EHSI GBCS BMGL AMS HLYK BICX PIII SYRA HCA XTER:FRE SAU:4013 XKLS:5225 THC BSP:RDOR3 DVA NSE:APOLLOHOSP XTER:FME BOM:543220

Other Exchanges CCEL:USA ZCY:Germany

Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677

Website https://www.cryo-cell.com

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

58GF Score

Get the complete analysis for STU:ZCY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.36

Price

€4.06

GF Value

View STU:ZCY Analysis

See ROCE % data for all stocks →